Envisia Therapeutics
Latest round
- Series A
Last raised
- Mar 2016
Total raised
- $36M
Investors
- 5
About Envisia Therapeutics
Envisia Therapeutics Inc.Founded in 2013, Envisia Therapeutics Inc. specializes in therapeutic innovations aimed at improving patient outcomes. The company is based in the United States and was acquired by Aerie Pharmaceuticals, Inc. in October 2017 for USD 25 mn. The acquisition marked a pivotal moment in the company's trajectory, allowing it to leverage Aerie's resources.Envisia Therapeutics specializes in the development and commercialization of innovative therapeutic solutions targeting various medical conditions. Their core product offerings include advanced therapeutic interventions designed to improve patient outcomes in areas such as chronic pain management and neurological disorders. These products employ technology and research methodologies, focusing on personalized medicine to address specific patient needs. Envisia Therapeutics primarily serves healthcare providers, including hospitals and specialty clinics, as well as patients seeking effective treatment options.Envisia Therapeutics generates revenue through direct sales of its therapeutic products and subscription-based services for healthcare providers. The company’s transactions are structured primarily as B2B engagements, where healthcare institutions purchase their offerings directly for integration into patient care programs. Pricing agreements are often negotiated based on volume with large healthcare networks.Following its acquisition in October 2017, Envisia Therapeutics plans to leverage Aerie Pharmaceuticals' capabilities to enhance its product portfolio. The upcoming rollout of new therapeutic solutions is anticipated, though specific launch dates have not been disclosed. The company aims to expand into additional European markets and increase its presence in North America, with targeted initiatives planned for the next few years.
Who invested in Envisia Therapeutics
5 investors across 3 rounds
See all investors in Envisia Therapeutics
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Envisia Therapeutics
Who invested in Envisia Therapeutics?
Envisia Therapeutics has 5 investors on record across 3 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Envisia Therapeutics raised?
Envisia Therapeutics has raised 3 venture rounds. Sign up free to see how much each round raised and the total.
When did Envisia Therapeutics last raise money?
Envisia Therapeutics's most recent round on record is a Series A, in Mar 2016.
What does Envisia Therapeutics do?
Envisia Therapeutics is a biotechnology company.
Where is Envisia Therapeutics headquartered?
Envisia Therapeutics is headquartered in US.
Which VCs invest in companies like Envisia Therapeutics?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back biotechnology companies at Envisia Therapeutics's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series A
Raising like Envisia Therapeutics? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.